PLx Pharma is a commercial-stage drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients are absorbed in the gastrointestinal tract via its clinically-validated and patent-protected PLxGuard technology. Co. has two Food and Drug Administration approved products, VAZALORE® 81 mg and VAZALORE® 325 mg, which are liquid-filled aspirin capsules for over-the-counter distribution. The complex inside the capsule allows for targeted release of aspirin, limiting its direct contact with the stomach lining. VAZALORE delivers absorption for pain relief plus the lifesaving benefits of aspirin. The PLXP average annual return since 2014 is shown above.
The Average Annual Return on the PLXP average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PLXP average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PLXP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|